In recognition of International Ataxia Awareness Day, observed annually on NeurologyLive® reviews 6 investigational agents ...
Exploring the Link Between Football Players and ALS: Brian Lin, PhD In a recent Q&A interview, Brian Lin, PhD, research ...
Neurology moves fast, and the assumptions that shape how we practice do not always keep up. Gray Areas is a NeurologyLive ...
In this episode, host Lindsay Ross, MD, is joined by joined by Rachel Galioto, PhD, a Cleveland Clinic neuropsychologist ...
Results recently published from the phase 2 HIMALAYA trial reported that SAR443820 did not slow functional decline, and was associated with more adverse events and treatment discontinuations in ...
Final 15-month phase 1/2 data showed SKY-0515 improved cUHDRS scores and lowered mutant huntingtin protein in early-stage Huntington disease.
The professor of neurology at the University of Cincinnati discussed why disparities persist in secondary stroke prevention and how growing awareness of social determinants of health is helping to ...
Twelve observational studies (1997–2025) demonstrated a bidirectional migraine–colic association, including both maternal ...
Thirty-day headache history dominated feature importance; rolling mean severity alone contributed 37.6% and 30-day window features 56.3%, versus 11.1% for prodromal symptom features. Forecast ...
Welcome to NeurologyLive® Brain Games! This weekly quiz series, which goes live every Sunday morning, will feature questions ...
A retrospective cohort study found DTI-ALPS, a glymphatic function marker, did not independently predict survival in ...
The FDA has granted fast track designation to Scholar Rock’s apitegromab (Isembyld), a muscle-targeting therapy recently approved for the treatment of spinal muscular atrophy (SMA), for patients ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results